Top Story Today
Three Phase 3 Wins, Zero Stumbles: An LSD Pill Is Headed to the FDA
Analysts peg FDA approval odds for DT120 at roughly 65–75%. Definium Therapeutics' DT120, a pharmaceutical-grade LSD tablet that dissolves on your tongue, just completed a clean sweep of three consecutive Phase 3 trials across anxiety and depression, with no safety flags and no ambiguous readouts. A single dose appears to deliver therapeutic benefits lasting 12 weeks or more, offering a fundamentally different model than daily SSRIs. If approved by the projected end of 2027, DT120 would become the first classic psychedelic drug ever greenlit for a major psychiatric disorder.
Why it matters: Three consecutive pivotal wins across two psychiatric conditions put psychedelic-assisted therapy on a clear regulatory path, potentially opening the door for an entirely new treatment paradigm in mental health where a single dose replaces months of daily medication.
Read more →Clinical Trials & Regulatory
Two Shots a Year, Two Infections Out of 2,180 People
Gilead's twice-yearly lenacapavir injection produced just 2 HIV infections out of 2,180 participants in the PURPOSE 2 trial, crushing daily Truvada by 89%. The results held across diverse populations and geographies. The science is now ironclad; the real battle is access, with a U.S. list price of $28,218 per year versus modeled generic costs of roughly $40.
Read more →The Drug That Failed Its Pivotal Trial and Still Got FDA Approval
Stealth BioTherapeutics won the first-ever FDA approval for Barth syndrome, a mitochondrial disease with only an estimated 230–250 known cases worldwide. The twist: the pivotal trial missed both primary endpoints. The FDA used the accelerated pathway and a surrogate muscle-strength measure to greenlight it anyway, plus handed Stealth a priority review voucher worth roughly $100 million.
Read more →Brain Cancer Imaging Takes a Step Forward — but Not Yet Across the Finish Line
The FDA issued a Complete Response Letter for Telix Pharmaceuticals' Pixclara, a PET imaging agent designed specifically for glioma, citing concerns about quantitative consistency and requesting additional clinical evidence. Unlike standard MRI, which can't distinguish real tumor recurrence from post-treatment brain swelling, Pixclara targets amino acid transporters on glioma cells to show actual tumor biology. It's not yet approved, but for the roughly 50,000 Americans living with glioma, the technology still represents a promising step toward greater diagnostic clarity.
Read more →Oncology Battlegrounds
J&J Posts Record Lung Cancer Survival, but the Stats Say 'Not Proven'
J&J's amivantamab combo delivered 34.3 months median survival in EGFR exon 20 insertion lung cancer, the longest ever reported. The problem: the result wasn't statistically significant (p=0.307), largely because 76% of control patients crossed over to amivantamab. Adjusted analyses look much better, but the headline number comes with a real asterisk.
Read more →The Oral Pill Coming for J&J's Lung Cancer Throne
Cullinan and Taiho's zipalertinib posted 14.5 months progression-free survival in first-line EGFR exon 20 insertion NSCLC. It's a pill, not an IV infusion. The FDA decision is set for February 2027, and overall survival data is still maturing.
Read more →Gilead's Lung Cancer Moonshot Crashes Back to Earth
Trodelvy missed both primary endpoints in the EVOKE-03 trial, failing to prove its combo with Keytruda could beat Keytruda alone in first-line PD-L1-high lung cancer. Shares dropped roughly 3%. The failure punches a hole in Gilead's oncology expansion thesis and raises broader doubts about whether TROP-2 antibody-drug conjugates can work beyond breast cancer.
Read more →Cell Therapy & Platform Shifts
The Company That Pioneered Off-the-Shelf CAR-T Just Scaled Way Back
Cellectis, one of the original champions of allogeneic CAR-T, significantly scaled back its cancer programs and shifted its focus toward in vivo gene editing for cardiovascular diseases. After a decade of work and zero approvals across the entire off-the-shelf CAR-T field, the move signals a broader industry reckoning with donor-derived cell therapy.
Read more →What If Your Body Could Build Its Own Cancer-Killing Cells?
Vyriad dosed its first patient in a Phase 1 trial of VV169, an in vivo CAR-T therapy that turns the patient's body into a cell therapy factory. One IV infusion, no cell collection, no manufacturing delays. Big Pharma is already circling the space: AbbVie, Lilly, and AstraZeneca have all made billion-dollar bets on similar approaches.
Read more →Funding & Financings
A Billion-Dollar IPO Bet on a Protein Most People Have Never Heard Of
Electra Therapeutics filed for a nearly $1 billion IPO on Nasdaq, aiming to raise up to $346.7 million around its SIRP-targeting immunology platform. With a Phase 2/3 registrational trial underway in a rare immune disorder and blue-chip backers including Sanofi and OrbiMed, the deal is a key test of whether the biotech IPO recovery has real legs heading into Q4.
Read more →